SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act
April 18, 2005
--------------
Date of Report
(Date of earliest event reported)
LipidViro Tech, Inc.
--------------------
(Exact name of registrant as specified in its charter)
Utah 000-49655 87-0678927
---- --------- ----------
(State or other (Commission File Number) (IRS Employer
jurisdiction of Identification No.)
incorporation)
1338 South Foothill Dr. #126
Salt Lake City, Utah 84108
--------------------------
(Address of Principal Executive Offices)
(801) 583-9900
--------------
(Registrant's Telephone Number)
N/A
(Former Name or Former Address if changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of
the following provisions (see general instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14-a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Agreement.
------------------------------------------
On April 18, 2005, LipidViro Tech, Inc. (our "Company," "we," "our," "us"
or words of similar import) executed a Securities Purchase Option Agreement
(the "Agreement") with Lombard, Inc. ("Lombard"), whereby we purchased for
$1.00, an option to acquire 7,875,000 shares of our common stock, for a period
of 48 months from the date of the Agreement, for a purchase price of $600,000.
The Agreement is attached hereto and incorporated herein by reference. See
Item 9.01.
Item 9.01 Financial Statements and Exhibits.
----------------------------------
(c) Exhibits.
Description of Exhibit Exhibit Number
---------------------- --------------
Securities Purchase Option Agreement 10.1
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Registrant has
duly caused this Current Report to be signed on its behalf by the undersigned
hereunto duly authorized.
LIPIDVIRO TECH, INC.
Dated: 5/3/2005 /s/ Kenneth P. Hamik
-------- ----------------------
Kenneth P. Hamik
President and Director